PL1945186T3 - Stałe doustne kompozycje farmaceutyczne do dawkowania raz na dobę zawierające pregabalinę, środek tworzący matrycę i środek spęczniający - Google Patents

Stałe doustne kompozycje farmaceutyczne do dawkowania raz na dobę zawierające pregabalinę, środek tworzący matrycę i środek spęczniający

Info

Publication number: PL1945186T3
Authority: PL; Poland
Prior art keywords: pharmaceutical compositions; once daily; solid oral; oral pharmaceutical; matrix forming
Prior art date: 2005-11-02

Application number

PL06809154T

Other languages

English (en)

Inventor

Howard Norman Bockbrader

Yun Hyung Cho

Santiago Steven Diaz

Majid Mahjour

Thomas Daniel Reynolds

Pushpa Ganapathi Shao

Zezhi Jesse Shao

Jiansheng Wan

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-02

Filing date

2006-10-23

Publication date

2014-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1945186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-10-23 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2014-05-30 Publication of PL1945186T3 publication Critical patent/PL1945186T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Inorganic Chemistry (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL06809154T 2005-11-02 2006-10-23 Stałe doustne kompozycje farmaceutyczne do dawkowania raz na dobę zawierające pregabalinę, środek tworzący matrycę i środek spęczniający PL1945186T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73258905P	2005-11-02	2005-11-02
PCT/IB2006/003063 WO2007052125A2 (en)	2005-11-02	2006-10-23	Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
EP06809154.5A EP1945186B1 (en)	2005-11-02	2006-10-23	Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent

Publications (1)

Publication Number	Publication Date
PL1945186T3 true PL1945186T3 (pl)	2014-05-30

Family

ID=37965070

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06809154T PL1945186T3 (pl)	2005-11-02	2006-10-23	Stałe doustne kompozycje farmaceutyczne do dawkowania raz na dobę zawierające pregabalinę, środek tworzący matrycę i środek spęczniający

Country Status (33)

Country	Link
US (11)	US20070269511A1 (pl)
EP (1)	EP1945186B1 (pl)
JP (1)	JP4334610B2 (pl)
KR (1)	KR101012533B1 (pl)
CN (1)	CN101330907B (pl)
AP (1)	AP2008004465A0 (pl)
AR (1)	AR058175A1 (pl)
AU (1)	AU2006310217B2 (pl)
BR (1)	BRPI0618211B8 (pl)
CA (1)	CA2628200C (pl)
CR (1)	CR9950A (pl)
DK (1)	DK1945186T3 (pl)
DO (1)	DOP2006000241A (pl)
EA (1)	EA012377B1 (pl)
EC (1)	ECSP088422A (pl)
ES (1)	ES2449231T3 (pl)
GT (1)	GT200600474A (pl)
IL (1)	IL190827A (pl)
MA (1)	MA30135B1 (pl)
ME (1)	ME00482B (pl)
NL (1)	NL2000281C2 (pl)
NO (1)	NO20081816L (pl)
NZ (1)	NZ567414A (pl)
PE (1)	PE20070693A1 (pl)
PL (1)	PL1945186T3 (pl)
PT (1)	PT1945186E (pl)
RS (1)	RS20080181A (pl)
SI (1)	SI1945186T1 (pl)
TN (1)	TNSN08194A1 (pl)
TW (1)	TWI330080B (pl)
UY (1)	UY29890A1 (pl)
WO (1)	WO2007052125A2 (pl)
ZA (1)	ZA200803115B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU714980B2 (en)	1996-07-24	2000-01-13	Warner-Lambert Company Llc	Isobutylgaba and its derivatives for the treatment of pain
ATE542525T1 (de) *	2007-10-16	2012-02-15	Pharmathen Sa	Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung
WO2009080365A1 (en) *	2007-12-21	2009-07-02	Synthon B.V.	Pregabalin salts
MY150971A (en) *	2008-07-09	2014-03-31	Melaleuca Inc	Mineral amino acid polysaccharide complex
RU2012100709A (ru) *	2009-06-12	2013-07-20	Майкро Лэбз Лимитед	Новые фармацевтические композиции, содержащие прегабалин
WO2010150221A1 (en)	2009-06-25	2010-12-29	Wockhardt Research Centre	Taste masked pharmaceutical compositions of pregabalin
KR101317592B1 (ko) *	2009-10-28	2013-10-15	씨제이제일제당 (주)	프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
WO2011104652A2 (en) *	2010-02-24	2011-09-01	Pfizer Inc.	Veterinary compositions
HU230031B1 (hu) *	2010-03-01	2015-05-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
JP5905872B2 (ja) *	2010-04-07	2016-04-20	ルピン・リミテッド	タペンタドールの制御放出医薬組成物
TR201005241A1 (tr)	2010-05-25	2012-01-23	Sanovel �La� San. Ve T�C. A.�.	Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389933A1 (en)	2010-05-25	2011-11-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Controlled-Release Pregabalin Compositions
EP2389934A1 (en)	2010-05-25	2011-11-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Controlled-Release Tablet Formulations of Pregabalin
US20130078290A1 (en) *	2010-06-01	2013-03-28	Rubicon Research Private Limited	Gastroretentive Dosage Forms Of GABA Analogs
CA2801620A1 (en) *	2010-07-06	2012-01-12	Gruenenthal Gmbh	Novel gastro-retentive dosage forms comprising a gaba analog and an opioid
EP2415460A1 (de) *	2010-08-03	2012-02-08	ratiopharm GmbH	Orale Darreichungsform von Pregabalin
WO2012035559A2 (en) *	2010-09-17	2012-03-22	Panacea Biotec Ltd	Sustained release pharmaceutical compositions comprising pregabalin
WO2012084126A2 (en)	2010-12-02	2012-06-28	Ucb Pharma Gmbh	Formulation of lacosamide
EA017542B1 (ru) *	2011-05-24	2013-01-30	Плива Кроэйша Лтд.	Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
KR101724024B1 (ko) *	2011-07-26	2017-04-06	주식회사유한양행	2상 방출-제어 시스템에 의한 프레가발린을 함유하는 서방성 정제
CN102908327B (zh) *	2011-08-05	2015-03-11	江苏恒瑞医药股份有限公司	伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) *	2011-08-26	2014-09-17	근화제약주식회사	프레가발린을 포함하는 서방성 제제
CA2863371A1 (en) *	2012-01-30	2013-08-08	Ranbaxy Laboratories Limited	Pregabalin gr tablets
EP2809304A1 (en)	2012-01-30	2014-12-10	Ranbaxy Laboratories Limited	Gastroretentive tablets
CN102743357A (zh) *	2012-06-26	2012-10-24	严轶东	一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
WO2014060952A1 (en)	2012-10-16	2014-04-24	Ranbaxy Laboratories Limited	Osmotic floating tablets
IN2014MU00198A (pl) *	2014-01-21	2015-08-28	Intas Pharmaceuticals Ltd
WO2015114509A1 (en)	2014-01-28	2015-08-06	Ranbaxy Laboratories Limited	Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (ko) *	2014-04-07	2021-02-26	영진약품 주식회사	안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
CN105979936A (zh) *	2014-10-24	2016-09-28	江苏恒瑞医药股份有限公司	一种普瑞巴林缓释制剂
CN104906064B (zh) *	2015-05-15	2017-12-22	中国药科大学	一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) *	2015-05-20	2017-08-29	Altera Corporation	Pipelined cascaded digital signal processing structures and methods
MA44212A (fr) *	2015-05-26	2018-12-26	Isa Odidi	Prégabaline à libération prolongée contrôlée
CN104840443B (zh) *	2015-05-27	2018-04-27	齐鲁制药有限公司	含活性成分普瑞巴林的药物组合物
WO2017058869A1 (en)	2015-09-29	2017-04-06	Acorda Therapeutics, Inc.	Sustained release compositions of 4-aminopyridine
AU2017300185B2 (en) *	2016-07-17	2023-02-02	Mapi Pharma Ltd.	Extended release dosage forms of pregabalin
JP6919119B2 (ja) *	2017-01-23	2021-08-18	日新製薬株式会社	３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) *	2017-07-31	2019-08-29	大原薬品工業株式会社	プレガバリン並びに好適な賦形剤を含有する固形製剤
WO2019146642A1 (ja) *	2018-01-24	2019-08-01	大原薬品工業株式会社	γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
TW202002958A (zh) *	2018-03-22	2020-01-16	日商日東電工股份有限公司	含普瑞巴林（ｐｒｅｇａｂａｌｉｎ）之組成物的製造方法及含普瑞巴林之組成物
US11938222B2 (en)	2018-06-13	2024-03-26	Beijing Tide Pharmaceutical Co., Ltd.	Pregabalin sustained release composition and method for preparing the same
CN111053749B (zh) *	2018-10-16	2022-07-15	北京泰德制药股份有限公司	一种普瑞巴林缓释组合物及其制备方法
CN110585153A (zh) *	2018-06-13	2019-12-20	北京泰德制药股份有限公司	一种普瑞巴林缓释组合物及其制备方法
WO2020006372A1 (en) *	2018-06-28	2020-01-02	Mylan Inc.	Pregabalin extended-release fomulations
CN109044981B (zh) *	2018-08-07	2021-02-19	广州帝奇医药技术有限公司	一种普瑞巴林胃漂浮型缓释片及其制备方法
EP3760190B1 (en)	2019-07-03	2023-05-24	Alvogen, Inc.	Controlled-release tablets of pregabalin, method of making, and method of use thereof
US12012413B2 (en) *	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy
CN110974798A (zh) *	2019-12-19	2020-04-10	江苏优仿医药科技有限公司	药物组合物、缓释片剂及其制备方法
CN115916744A (zh) *	2020-07-20	2023-04-04	四川海思科制药有限公司	一种稠合三环γ-氨基酸衍生物的缓释药物制剂及其制备方法
CN115105478B (zh) *	2021-03-17	2024-07-09	上海云晟研新生物科技有限公司	一种拉考沙胺药物组合物、其制备方法及应用
CN113577036B (zh) *	2021-05-31	2023-04-04	石药集团欧意药业有限公司	一种普瑞巴林胃漂浮缓释片及其制备方法
GB2624861A (en) *	2022-11-28	2024-06-05	Orbit Pharma Ltd	Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
GB2639602A (en)	2024-03-19	2025-10-01	Novumgen Ltd	An orodispersible tablet of pregabalin and its process of preparation
CN120324357B (zh) *	2025-06-03	2025-10-24	上海国创医药股份有限公司	一种普瑞巴林缓释组合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0124363B1 (en)	1983-05-02	1990-12-19	Diamond Scientific Co.	Photochemical decontamination treatment of whole blood or blood components
DE3928183A1 (de)	1989-08-25	1991-02-28	Goedecke Ag	Lactamfreie cyclische aminosaeuren
US6197819B1 (en) *	1990-11-27	2001-03-06	Northwestern University	Gamma amino butyric acid analogs and optical isomers
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it)	1996-02-19	1998-03-31	Jagotec Ag	Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en)	1997-05-13	2001-08-07	Purdue Research Foundation	Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
AU8699298A (en)	1997-08-11	1999-03-01	Alza Corporation	Prolonged release active agent dosage form adapted for gastric retention
IN186245B (pl) *	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
HU228772B1 (en)	1998-05-15	2013-05-28	Warner Lambert Co	Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
DK1077692T3 (da)	1998-05-15	2004-12-06	Warner Lambert Co	Aminosyrestabiliserede gabapentin- og pregabalinpræparater og fremgangsmåder til fremstilling deraf
US6891059B2 (en) *	2000-01-27	2005-05-10	Warner-Lambert Company	Asymmetric synthesis of pregabalin
DE10014588A1 (de) *	2000-03-27	2001-10-04	Basf Ag	Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
PT1289364E (pt)	2000-06-16	2004-04-30	Teva Pharma	Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
US6488962B1 (en)	2000-06-20	2002-12-03	Depomed, Inc.	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001268722B8 (en)	2000-06-23	2005-09-29	Teva Pharmaceutical Industries Ltd.	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CA2356829A1 (en) *	2000-09-22	2002-03-22	Warner-Lambert Company	Method for treating asthma using pregabalin
US7056951B2 (en)	2000-09-26	2006-06-06	Mutual Pharmaceutical Co., Inc.	Stable solid dosage forms of amino acids and processes for producing same
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
CA2537837A1 (en) *	2003-09-11	2005-03-24	Xenoport, Inc.	Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005041926A1 (en)	2003-10-31	2005-05-12	Alza Corporation	Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid

2006
- 2006-10-17 NL NL2000281A patent/NL2000281C2/nl not_active IP Right Cessation
- 2006-10-23 DK DK06809154.5T patent/DK1945186T3/en active
- 2006-10-23 JP JP2008538441A patent/JP4334610B2/ja active Active
- 2006-10-23 WO PCT/IB2006/003063 patent/WO2007052125A2/en not_active Ceased
- 2006-10-23 EA EA200800931A patent/EA012377B1/ru not_active IP Right Cessation
- 2006-10-23 RS RSP-2008/0181A patent/RS20080181A/sr unknown
- 2006-10-23 BR BRPI0618211A patent/BRPI0618211B8/pt active IP Right Grant
- 2006-10-23 NZ NZ567414A patent/NZ567414A/en unknown
- 2006-10-23 ES ES06809154.5T patent/ES2449231T3/es active Active
- 2006-10-23 ME MEP-2008-761A patent/ME00482B/me unknown
- 2006-10-23 PL PL06809154T patent/PL1945186T3/pl unknown
- 2006-10-23 PT PT68091545T patent/PT1945186E/pt unknown
- 2006-10-23 CN CN2006800411407A patent/CN101330907B/zh active Active
- 2006-10-23 AU AU2006310217A patent/AU2006310217B2/en active Active
- 2006-10-23 CA CA2628200A patent/CA2628200C/en not_active Expired - Fee Related
- 2006-10-23 KR KR1020087010794A patent/KR101012533B1/ko active Active
- 2006-10-23 SI SI200631740T patent/SI1945186T1/sl unknown
- 2006-10-23 AP AP2008004465A patent/AP2008004465A0/xx unknown
- 2006-10-23 EP EP06809154.5A patent/EP1945186B1/en active Active
- 2006-10-30 PE PE2006001329A patent/PE20070693A1/es not_active Application Discontinuation
- 2006-10-31 AR ARP060104778A patent/AR058175A1/es not_active Application Discontinuation
- 2006-10-31 GT GT200600474A patent/GT200600474A/es unknown
- 2006-10-31 UY UY29890A patent/UY29890A1/es not_active Application Discontinuation
- 2006-11-01 TW TW095140374A patent/TWI330080B/zh active
- 2006-11-01 DO DO2006000241A patent/DOP2006000241A/es unknown
- 2006-11-02 US US11/555,988 patent/US20070269511A1/en not_active Abandoned
2008
- 2008-04-09 ZA ZA200803115A patent/ZA200803115B/xx unknown
- 2008-04-13 IL IL190827A patent/IL190827A/en active IP Right Grant
- 2008-04-14 NO NO20081816A patent/NO20081816L/no not_active Application Discontinuation
- 2008-04-30 EC EC2008008422A patent/ECSP088422A/es unknown
- 2008-04-30 TN TNP2008000194A patent/TNSN08194A1/fr unknown
- 2008-05-02 MA MA30892A patent/MA30135B1/fr unknown
- 2008-05-02 CR CR9950A patent/CR9950A/es not_active Application Discontinuation
2011
- 2011-10-06 US US13/267,352 patent/US20120029081A1/en not_active Abandoned
2012
- 2012-05-16 US US13/472,704 patent/US20120232149A1/en not_active Abandoned
- 2012-12-06 US US13/706,971 patent/US20130102675A1/en not_active Abandoned
2013
- 2013-07-22 US US13/947,433 patent/US20130303618A1/en not_active Abandoned
2014
- 2014-02-17 US US14/181,785 patent/US8945620B2/en active Active
- 2014-12-15 US US14/570,115 patent/US9144559B2/en active Active
2015
- 2015-08-20 US US14/831,205 patent/US20150352066A1/en not_active Abandoned
2016
- 2016-03-18 US US15/074,042 patent/US20160250147A1/en not_active Abandoned
2017
- 2017-01-30 US US15/418,907 patent/US20170136125A1/en not_active Abandoned
- 2017-08-25 US US15/686,549 patent/US10022447B2/en active Active

Also Published As

Publication number	Publication date
CA2628200A1 (en)	2007-05-10
JP4334610B2 (ja)	2009-09-30
GT200600474A (es)	2007-06-08
BRPI0618211A2 (pt)	2011-08-23
NZ567414A (en)	2011-09-30
ME00482B (me)	2011-10-10
US20150094371A1 (en)	2015-04-02
BRPI0618211B8 (pt)	2021-05-25
TWI330080B (en)	2010-09-11
ES2449231T3 (es)	2014-03-18
BRPI0618211B1 (pt)	2020-11-17
DOP2006000241A (es)	2007-05-31
JP2009514847A (ja)	2009-04-09
US10022447B2 (en)	2018-07-17
UY29890A1 (es)	2007-05-31
US20170348420A1 (en)	2017-12-07
CN101330907A (zh)	2008-12-24
EA200800931A1 (ru)	2008-10-30
NL2000281C2 (nl)	2007-08-07
US20150352066A1 (en)	2015-12-10
US20120232149A1 (en)	2012-09-13
IL190827A0 (en)	2008-12-29
EP1945186B1 (en)	2014-01-22
MA30135B1 (fr)	2009-01-02
SI1945186T1 (sl)	2014-03-31
AU2006310217B2 (en)	2012-08-16
AR058175A1 (es)	2008-01-23
KR20080059427A (ko)	2008-06-27
IL190827A (en)	2012-08-30
EP1945186A2 (en)	2008-07-23
US20140163103A1 (en)	2014-06-12
AU2006310217A1 (en)	2007-05-10
US20130303618A1 (en)	2013-11-14
KR101012533B1 (ko)	2011-02-07
ECSP088422A (es)	2008-05-30
WO2007052125A2 (en)	2007-05-10
AP2008004465A0 (en)	2008-06-30
US20070269511A1 (en)	2007-11-22
ZA200803115B (en)	2009-09-30
US20130102675A1 (en)	2013-04-25
US20170136125A1 (en)	2017-05-18
CA2628200C (en)	2011-01-25
RS20080181A (sr)	2009-07-15
US20160250147A1 (en)	2016-09-01
EA012377B1 (ru)	2009-10-30
HK1126394A1 (en)	2009-09-04
US8945620B2 (en)	2015-02-03
DK1945186T3 (en)	2014-03-17
WO2007052125A3 (en)	2007-09-07
NO20081816L (no)	2008-05-08
TW200803831A (en)	2008-01-16
CR9950A (es)	2008-05-28
CN101330907B (zh)	2012-08-29
PT1945186E (pt)	2014-03-06
TNSN08194A1 (fr)	2009-10-30
PE20070693A1 (es)	2007-08-11
NL2000281A1 (nl)	2007-05-03
US9144559B2 (en)	2015-09-29
US20120029081A1 (en)	2012-02-02

Publication	Publication Date	Title
IL190827A0 (en)	2008-12-29	Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
ZA200707022B (en)	2009-08-26	A solid pharmaceutical dosage formulation
IL182020A0 (en)	2007-07-24	Pharmaceutical composition comprising diclofenac
IL233925A0 (en)	2014-09-30	Pharmaceutical dose for oral administration in the form of tiny particles to prevent incorrect use
IL193776A0 (en)	2009-09-22	A pharmaceutical composition containing an aminosalicylate active agent
ZA200802947B (en)	2009-12-30	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
ZA200606229B (en)	2009-12-30	A pharmaceutical composition
SG131857A1 (en)	2007-05-28	δD-CRYSTALLINE FORM OF IV ABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
GB0413730D0 (en)	2004-07-21	A pharmaceutical composition and its use
GB0413729D0 (en)	2004-07-21	A pharmaceutical composition and its use
SG125233A1 (en)	2006-09-29	Gamma D-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
IL189631A0 (en)	2008-06-05	A controlled release pharmaceutical composition containing hypromellose
PL1973423T3 (pl)	2017-08-31	Preparat zawierający kompozycję zawierającą polifenole i izomaltulozę
WO2007016284A3 (en)	2007-03-29	Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
ZA200700511B (en)	2008-09-25	A pharmaceutical composition comprising gabapentin
SG126113A1 (en)	2006-10-30	Indany-piperazine compounds, a process for their preparation and pharmaceutical compositions containing them
GB0400452D0 (en)	2004-02-11	A pharmaceutical composition
ZA200603810B (en)	2007-08-29	Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
SG121999A1 (en)	2006-05-26	New benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
IL190830A0 (en)	2008-12-29	Stable pharmaceutical formulaions containing escitalopram and bupropion
ZA200603809B (en)	2007-08-29	Phenylpyridylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200800833B (en)	2009-04-29	New 1H-indole-pyridinecarboxamide and 1H-indolepiperidinecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200606277B (en)	2007-04-25	Polysubstituted 1,1-pyridyloxycyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200606276B (en)	2007-12-27	Polysubstituted 1,1-pyridylaminocyclopropanamine compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200607532B (en)	2008-05-28	Association between agomelatine and a thymoregulatory agent, and pharmaceutical compositions containing it